KEYSTONE NANO, INC.
| 1981 Pine Hall Road
State College, PA, 16801-2435
|Socially and Economically Disadvantaged:||N|
|Number of Employees:||8|
DESCRIPTION (provided by applicant): Most current chemotherapeutics have non-specific mechanisms of action and poor biodistribution profiles which result in dose-limiting toxicities tha prevent optima ...SBIR Phase I 2014 Department of Health and Human Services
'Keystone Nano, building on a successful partnership with Nalco and co-development programs with Johnson and Johnson, Eli Lilly, United Therapeutics, NanoTherapies, and the NCI, will develop multifunc ...SBIR Phase I 2010 Department of Health and Human Services
DESCRIPTION (provided by applicant): Most current chemotherapeutics are untargeted formulations that have little to no selectivity for cancerous tissue. As a result, these drugs often cause damage to ...SBIR Phase I 2009 Department of Health and Human Services